Semaglutide for Smoking Cessation in Patients With Diabetes (NCT07059377) | Clinical Trial Compass
RecruitingPhase 3
Semaglutide for Smoking Cessation in Patients With Diabetes
Canada100 participantsStarted 2026-02-13
Plain-language summary
To assess the feasibility of conducting a randomized controlled trial (RCT) to determine the effectiveness of semaglutide as an adjunct to combination NRT in supporting smoking cessation for patients with diabetes.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Adults (18 years or older) with type 2 diabetes
* Currently residing in Ontario
* Smoke at least five cigarettes per day and willing to reduce or quit smoking within the next 6 months
* Stable HbA1c ≥7.0% - 10% with no more than a 1% change over the last 3 to 6 months.
* Have not used GLP-1 receptor agonists in the past six months.
* Able to provide informed consent
Exclusion Criteria:
* Pregnant or breastfeeding individuals
* Contraindication to NRT or GLP-1 RA.
* Current daily use of NRT or a GLP1 RA.
* Use of bupropion, cytisine, and varenicline within the last 7 days.
* Use of a DPP-IV inhibitor within the last 7 days.
* Initiation of a new diabetes medication within the last 3 months.
* As per the product monograph, participants with the following diagnoses or disorders will be excluded;
* Personal or family history of medullary thyroid cancer
* Personal or family history of Multiple Endocrine Neoplasia syndrome type 2
* Diabetic ketoacidosis
* Type I diabetes
* Acute pancreatitis or pancreatic cancer
* Acute, chronic or end-stage renal failure
* Tachyarrhythmias
* Unable to engage in follow-up for any reason (for example an acute mental illness, cognitive impairment, unable to speak English or French).
* Other conditions deemed by the study team to interfere with participation or outcomes in the opinion of the study investigator (for example acutely unwell, life expectancy less than 1 year).
What they're measuring
1
Project success
Timeframe: 12 months
Trial details
NCT IDNCT07059377
SponsorOttawa Heart Institute Research Corporation